Othelium Therapeutics 

Cambridge, MA Biologics, Cardiovascular, renal, endocrine, & metabolic, Immunology & inflammation
Overview

Othelium Therapeutics is developing first-in-class biologics to restore endothelial function and treat microvascular disease and heart failure.

Leadership
  • Tim Hla, PhD

    Investigator, Vascular Biology Program, Boston Children's Hospital; Chair and Professor, Patricia K. Donohoe, Department of Surgery, Harvard Medical School